Jazz Pharmaceuticals Plc

JAZZ

Statistics

$140.55Share Price
$8.6 BMarket Cap
6.6%EBIT / EV
5.8%FCF / EV
14.8%ROIC
13.2%Cash ROIC
19.9%3yr Avg Revenue Growth
3.10Current Ratio
star logo

Business Model Diligence

We do not yet have Business Model Diligence for this stock.

Statistical Diligence

check mark The EBIT / Enterprise Value of 6.6% ranks as Above Average.
check mark The Free Cash Flow / Enterprise Value of 5.8% ranks as Above Average.
check mark The Return on Invested Capital Value of 14.8% ranks as Above Average.
check mark The Cash Return on Capital Value of 13.2% ranks as Above Average.
check mark The 3 Year Average Revenue Growth Value of 19.9% ranks as Above Average.
check mark Near-term Financial Health appears to be Very Good. The Current Ratio is 3.10.

Company Description

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd on January 18, 2012 and is headquartered in Dublin, Ireland.

Calculations

You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.